TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $533,898 | +14.0% | 34,759 | +56.2% | 0.00% | +100.0% |
| Q4 2022 | $468,128 | -40.4% | 22,260 | -30.1% | 0.00% | -50.0% |
| Q3 2022 | $785,000 | +119.3% | 31,850 | +176.6% | 0.00% | +100.0% |
| Q4 2021 | $358,000 | -67.7% | 11,514 | -74.8% | 0.00% | -75.0% |
| Q3 2021 | $1,108,000 | +95.4% | 45,696 | +119.8% | 0.00% | +33.3% |
| Q4 2020 | $567,000 | – | 20,791 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |